GOS to Reduce Symptom Severity in IBS
A legfontosabb adatok
- Ki végzi
- Clasado
- Hol
- Belgium, Egyesült Királyság és Hollandia9 helyszín, 3 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 153 fő vett részt
- Kezdés
- 2021. okt. 26.
- Befejezés
- 2024. aug. 6.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Galacto-oligosaccharides (GOS)
- Maltodextrine
- A regiszteradat frissítve
- 2024. október 18.
Ki vehet részt
- Életkor
- 18 év – 65 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Patients who have been diagnosed with IBS by a medically trained person/Health Care Professional (HCP)
- IBS diagnosis to be confirmed according to the Rome-IV criteria by a primary or secondary care clinician, including a gastroenterologist, at study entry
- An IBS Symptom Severity Scale score of ≥125 points at baseline
- Male or female between 18 and 64 years of age (age ranges included)
- Possession of a smartphone
- Willing and eligible to provide consent and comply with protocol and product intake
Ki nem vehet részt
- Use of products marketed as prebiotics, probiotics or synbiotics within 4 weeks prior to study entry (e.g. Yakult, Actimel, Activia, VSL#3, Kefir); o Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion
- Systemic antibiotic or antimycotic treatment within 4 weeks prior to study entry
- Use of laxatives or antidiarrheal medication within 1 week prior to study entry
- An unstable antidepressant/antipsychotic treatment regimen within 3 months prior to study entry (i.e. treatment should be stable for at least 3 months prior to study entry)
- Subjects suffering from auto-immune disorders (e.g. Rheumatoid Arthritis, Systemic lupus erythematosus, Multiple Sclerosis, Graves' Disease) that require treatment with an immune modulator treatment or anti-inflammatory medication
- Surgical operations to the mouth or gastrointestinal tract within 4 weeks prior to study entry, or planned during the study; o Appendectomy within 6 months prior to study entry
- Recent unintended weight loss:; o >5% of total body weight within 6 months prior to study entry
- Excessive alcohol consumption (>14 units per week) and/or drug abuse
- Participation in other studies involving investigational or marketed products concomitantly or within 3 months prior to study entry
- Changes in diet, supplement or medication use likely to affect study outcomes (i.e. medication that influences GI function) within 4 weeks prior to study entry or planned during the study (at the discretion of the Investigator). For example, the following medications will influence GI function and changes must be avoided: opioids, prokinetics (domperidone, metoclopramide, prucalopride), antispasmodics (peppermint oil, buscopan), and acid suppressants (PPI, H2 blockers). Of note: the intake of fibres (e.g. psyllium husk) may be used provided that the participant has been using this as a supplement for more than 4 weeks prior to study participation and intake does not change during the course of participation
- Confirmed food allergy, with reported confirmation based on OFC, IgE, or skin prick test. Confirmation is patient-reported and not done within the scope of this study
- Galactosemia (galactose metabolism disorder)
- Severe illness(es) or medical condition(s), including gastrointestinal pathologies:; o GI ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, bowel resection, , bariatric surgery, acute or chronic diarrhoea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition
- Unclassifiable IBS (IBS-U) as determined by Investigator
- Confirmed lactose intolerance, defined as patients who report response to dietary elimination of lactose/dairy products. Confirmation is patient-reported and not done within the scope of this study
- Following diets likely to affect study outcomes, including:; o low FODMAP, KETO/high-fat, gluten free/coeliac, paleo, weight loss, caloric restriction, low-carb, 5:2/whole day energy restriction, Atkins/high-protein, sugar-free, single-food, juicing/any day of juicing, any other restriction diet (e.g. very low calory), or vegan diets (GOS is derived from cow's milk)
- Pregnancy and lactation, or plan to become pregnant during the study period
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
IBS is a highly prevalent bowel disorder, characterized by recurrent abdominal pain during bowel movements or a change in bowel habits. Typically, IBS patients experience constipation, diarrhoea or a mix of constipation and diarrhoea, as well as symptoms of abdominal bloating or distension. The chronic and bothersome nature of IBS symptoms negatively affects the quality of life of many patients. Because there are currently limited medical treatment options for IBS, it is important to study new treatments.
A teljes eredeti leírásKevesebb
IBS can (in part) be caused by an 'imbalance' of the bacteria residing in the intestinal tract. For instance, there may be a lower proportion of specific bacteria that are generally considered beneficial for a persons health. The consumption of non-digestible food ingredients, such as GOS, may stimulate the growth of these beneficial bacteria. GOS is a type of 'prebiotic', which is known to support health and wellbeing of consumers. By restoring the bacterial balance of the intestinal tract, the symptoms of IBS may be reduced after consumption of GOS.
The health effects of the study product (a specific GOS) used in current study was previously investigated in a small group of patients with IBS. Use of the study product indicated a reduction in the patients' symptoms, improvement in the patients' quality of life, and changes in patients' gut bacteria. It is therefore hypothesized that GOS / a specific GOS may reduce the symptom severity of patients with IBS.
This study further evaluates how GOS may improve symptoms of IBS.
A vizsgálat 2 csoportja
- GOS armA vizsgált kezelés
A single daily dose of a food supplement containing GOS for 8 weeks
Kezelés: Galacto-oligosaccharides (GOS)
- Placebo armPlacebo, összehasonlításként
A single daily dose of maltodextrin, matching in taste, smell, appearance, and solubility, but without active ingredients (i.e. GOS), for 8 weeks
Kezelés: Maltodextrine
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multi-centre, Randomized, Placebo-Controlled, Efficacy Study of Prebiotic Galacto-oligosaccharides on Gastrointestinal Symptom Severity in Patients With Irritable Bowel Syndrome
- A regiszteradat frissítve
- 2024. október 18.